These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 23735075

  • 1. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA, Pentimalli F, Esposito L, Giordano A.
    Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
    [Abstract] [Full Text] [Related]

  • 2. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M, Gortat A, Mondragón L, Bachs O, Pérez-Payá E.
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [Abstract] [Full Text] [Related]

  • 3. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P, Craig S, McInnes C.
    J Vis Exp; 2015 Oct 26; (105):e52441. PubMed ID: 26554946
    [Abstract] [Full Text] [Related]

  • 4. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA, Qayyum A, Rehman K, Tariq M, Akash MSH.
    Biomed Pharmacother; 2018 Nov 26; 107():1326-1341. PubMed ID: 30257348
    [Abstract] [Full Text] [Related]

  • 5. Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy.
    Wang YT, Jiang SQ, Zhang SL.
    Molecules; 2024 Jun 26; 29(13):. PubMed ID: 38998978
    [Abstract] [Full Text] [Related]

  • 6. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C, Novellino E, Chilin A, Lavecchia A, Marzaro G.
    Expert Opin Investig Drugs; 2016 Oct 26; 25(10):1215-30. PubMed ID: 27606939
    [Abstract] [Full Text] [Related]

  • 7. Promises and drawbacks of targeting cell cycle kinases in cancer.
    Pentimalli F, Giordano A.
    Discov Med; 2009 Dec 26; 8(43):177-80. PubMed ID: 20040266
    [Abstract] [Full Text] [Related]

  • 8. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM.
    Cancer Chemother Biol Response Modif; 2001 Dec 26; 19():165-88. PubMed ID: 11686013
    [Abstract] [Full Text] [Related]

  • 9. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L, Siu KT, Raje N.
    Semin Oncol; 2015 Dec 26; 42(6):788-800. PubMed ID: 26615126
    [Abstract] [Full Text] [Related]

  • 10. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V, Vylíčil J, Kryštof V.
    Expert Opin Ther Pat; 2015 Dec 26; 25(9):953-70. PubMed ID: 26161698
    [Abstract] [Full Text] [Related]

  • 11. Small-molecule cyclin-dependent kinase modulators.
    Senderowicz AM.
    Oncogene; 2003 Sep 29; 22(42):6609-20. PubMed ID: 14528286
    [Abstract] [Full Text] [Related]

  • 12. CDK inhibitors in cancer therapy: what is next?
    Malumbres M, Pevarello P, Barbacid M, Bischoff JR.
    Trends Pharmacol Sci; 2008 Jan 29; 29(1):16-21. PubMed ID: 18054800
    [Abstract] [Full Text] [Related]

  • 13. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
    Collins I, Garrett MD.
    Curr Opin Pharmacol; 2005 Aug 29; 5(4):366-73. PubMed ID: 15964238
    [Abstract] [Full Text] [Related]

  • 14. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
    Lv X, Ma X, Hu Y.
    Expert Opin Drug Discov; 2013 Aug 29; 8(8):991-1012. PubMed ID: 23668243
    [Abstract] [Full Text] [Related]

  • 15. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J, Chamrád I, Kryštof V.
    Future Med Chem; 2009 Dec 29; 1(9):1561-81. PubMed ID: 21425979
    [Abstract] [Full Text] [Related]

  • 16. Cyclin-dependent kinase modulators and cancer therapy.
    Gallorini M, Cataldi A, di Giacomo V.
    BioDrugs; 2012 Dec 01; 26(6):377-91. PubMed ID: 22928661
    [Abstract] [Full Text] [Related]

  • 17. Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
    Senderowicz AM.
    Prog Drug Res; 2005 Dec 01; 63():183-206. PubMed ID: 16265881
    [Abstract] [Full Text] [Related]

  • 18. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
    Goel B, Tripathi N, Bhardwaj N, Jain SK.
    Curr Top Med Chem; 2020 Dec 01; 20(17):1535-1563. PubMed ID: 32416692
    [Abstract] [Full Text] [Related]

  • 19. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
    Cirillo D, Pentimalli F, Giordano A.
    Curr Med Chem; 2011 Dec 01; 18(19):2854-66. PubMed ID: 21651493
    [Abstract] [Full Text] [Related]

  • 20. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
    Liu Y, Wan WZ, Li Y, Zhou GL, Liu XG.
    Oncotarget; 2017 Jan 24; 8(4):7181-7200. PubMed ID: 27769061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.